Results 211 to 220 of about 5,245,251 (341)

Antiplatelet therapy

Japanese Journal of Thrombosis and Hemostasis, 2006
Tsukasa OHMORI, Kazuomi KARIO
openaire   +2 more sources

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

Diabetic Medicine, EarlyView.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye, Ibi Erekosima, Adrian H. Heald, Gesiye Bozimo, Simon G. Anderson, Samuel Seidu, Kariba Akhidue, Adaeze Ugwu, Chioma Unachukwu, Ibitrokoemi Korubo, Kingsley Chukwuemeka Patrick‐Iwuanyanwu, Victoria Gomba, Uwoma Batubo, Victoria Akanatei, Victor Ken‐Uba, Iyeopu Siminialayi, Sokiprim Akoko, Justin Ideozu, Hamilton Opurum   +18 more
wiley   +1 more source

Adherence to Dual Antiplatelet Therapy Protocol in Acute Ischemic Stroke. [PDF]

Eur J Neurol
Martikainen L, ljäs P, Suomalainen OP, Tomppo L, Mannismäki L, Törmänen H, Girfanova M, Curtze S.   +7 more
europepmc   +1 more source

Antiplatelet therapy.

Nihon Naika Gakkai Zasshi, 1999
openaire   +2 more sources

The burden of diabetic foot ulcers in a multi‐ethnic Asian cohort

Diabetic Medicine, EarlyView.
Abstract Aims Diabetic foot ulcers (DFUs) are a major source of morbidity among individuals with diabetes mellitus (DM), imposing a substantial burden on healthcare systems. Our institution established a multidisciplinary service aiming to facilitate early specialist intervention for DFU management.
Zongwen Wee, Yong Mong Bee, Sueziani Binte Zainudin   +2 more
wiley   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice. [PDF]

Blood Adv
Yu H, Schroeder JA, Mattson JG, Gao C, Shi Q.   +4 more
europepmc   +1 more source

Appropriateness of the indication of anticoagulant therapy in patients with non-valvular atrial fibrillation [PDF]

, 2012
Baena Di­ez, JM, Espinosa Gonzalez, AB, Gonzalo Voltas, A, Lora Cabral, MA   +3 more
core  

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

New England Journal of Medicine, 2014
L. Mauri
semanticscholar   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source